Showing 1 to 4 of 4 results for nalmefene
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.View recommendations for TA325
This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.
This evidence summary has been replaced by NICE technology appraisal guidance 325.
NICE has approved the use of nalmefene to help people who are dependent on alcohol to cut down on the amount they drink.